Nitrosamine Impacted Drug Products Containing BCS IV Drug SubstancesBack to: Advancing Generic Drug Development 2025 Previous LessonSession 3: Q&A Panel (Advancing Generic Drug Development 2025)Lesson 5 within section Session 3: Common Deficiencies and Resolutions: Complex Drug Substances,Complex/Critical Excipients, and Complex Products. You must enroll in this course to access course content. Next LessonAddressing Potential Pitfalls in Nitrosamine Risk Assessment and ControlLesson 2 within section Session 4: Nitrosamines: Known Issues and Practical Advice. Presenter Gang Zhao, PhDResearch FellowDTPII | ORS | OGD | CDER | FDA Leave a Comment Cancel replyLogin with your Social IDYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment. Δ